GlassScriptPhysician profile
Julie Dunlap
NPI 1811442239
$4,942.62
in general payments reported to CMS, 2019-2025
35 companies · $772 in 2025
The $772 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,135 · 2022: $994 · 2023: $1,066 · 2024: $975 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810 · Education: $3.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.76 |
| Education | $3.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $595.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $586.94 | 2021-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $494.61 | 2021-2025 | |
| Astellas Pharma US INC | $465.48 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $432.55 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $239.59 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $229.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.08 | 2021-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $187.27 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $184.12 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $150.89 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $150.48 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| E.R. Squibb & Sons, L.L.C. | $145.68 | 2021-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $134.48 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $95.26 | 2022-2025 | Farxiga, Airsupra |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Dunlap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.